IPO News Archive
Verastem files for a $50 million IPO
Verastem, a biopharmaceutical company focused on developing small molecule drugs that target cancer stem cells, filed on Thursday with the SEC to raise up to $50 million in an initial public offering. The Cambridge, MA-based company was founded in 2010 and plans to list on the NASDAQ under the symbol VSTM
. UBS Investment Bank, Leerink Swann are the lead underwriters on the deal. Terms and timing are still to be determined.